%0 Journal Article %1 Ahmadvand2009 %A Ahmadvand, Davoud %A Rasaee, Mohammad J. %A Rahbarizadeh, Fatemeh %A Kontermann, Roland E. %A Sheikholislami, Farzaneh %D 2009 %J Molecular Immunology %K 2009 izi kontermann %N 8-9 %P 1814--1823 %R 10.1016/j.molimm.2009.01.021 %T Cell selection and characterization of a novel human endothelial cell specific nanobody %U https://www.ncbi.nlm.nih.gov/pubmed/19249099 %V 46 %X Antibody-based targeting of angiogenesis and vascular targeting therapy of cancer are extremely attractive conceptually and open new important diagnostic and therapeutic opportunities. Compelling evidence suggests that CD105 represents an ideal target for anti-angiogenic therapy and its presence in solid tumor vasculature has prognostic value. Camelids produce functional antibodies devoid of light chains and constant heavy chain domain (CH1). Nanobodies, the antigen-binding fragments of such heavy chain antibodies, are therefore comprised in one single domain. The aim of this study was to explore the possibilities of using anti-endoglin nanobody as an angiogenesis inhibitor. The anti-CD105 nanobody (AR-86a) was isolated from immune library by selections on purified antigens and target cells. Immunocytochemistry and FACS analysis showed that the purified nanobody reacted specifically with human umbilical vein endothelial cells (HUVECs) but not with other cell lines such as MDA-MB-453, Mel III, T-47D, MCF-7, AGO and HT 29. Further, selected nanobody potently inhibited proliferation of human endothelial cells and formation of capillary-like structures. This selected high affinity anti-endoglin nanobody may offer high specificity towards tumors with reduced side effects, and may be less likely to elicit drug resistance compared to conventional therapy. © 2009 Elsevier Ltd. All rights reserved. %Z Ahmadvand, DavoudRasaee, Mohammad JRahbarizadeh, FatemehKontermann, Roland ESheikholislami, FarzanehengEvaluation StudiesEnglandMol Immunol. 2009 May;46(8-9):1814-23. doi: 10.1016/j.molimm.2009.01.021. Epub 2009 Feb 27. %7 2009/03/03 %@ 0161-5890

@article{Ahmadvand2009, abstract = {Antibody-based targeting of angiogenesis and vascular targeting therapy of cancer are extremely attractive conceptually and open new important diagnostic and therapeutic opportunities. Compelling evidence suggests that CD105 represents an ideal target for anti-angiogenic therapy and its presence in solid tumor vasculature has prognostic value. Camelids produce functional antibodies devoid of light chains and constant heavy chain domain (CH1). Nanobodies, the antigen-binding fragments of such heavy chain antibodies, are therefore comprised in one single domain. The aim of this study was to explore the possibilities of using anti-endoglin nanobody as an angiogenesis inhibitor. The anti-CD105 nanobody (AR-86a) was isolated from immune library by selections on purified antigens and target cells. Immunocytochemistry and FACS analysis showed that the purified nanobody reacted specifically with human umbilical vein endothelial cells (HUVECs) but not with other cell lines such as MDA-MB-453, Mel III, T-47D, MCF-7, AGO and HT 29. Further, selected nanobody potently inhibited proliferation of human endothelial cells and formation of capillary-like structures. This selected high affinity anti-endoglin nanobody may offer high specificity towards tumors with reduced side effects, and may be less likely to elicit drug resistance compared to conventional therapy. {\textcopyright} 2009 Elsevier Ltd. All rights reserved.}, added-at = {2023-06-29T13:07:55.000+0200}, annote = {Ahmadvand, DavoudRasaee, Mohammad JRahbarizadeh, FatemehKontermann, Roland ESheikholislami, FarzanehengEvaluation StudiesEnglandMol Immunol. 2009 May;46(8-9):1814-23. doi: 10.1016/j.molimm.2009.01.021. Epub 2009 Feb 27.}, author = {Ahmadvand, Davoud and Rasaee, Mohammad J. and Rahbarizadeh, Fatemeh and Kontermann, Roland E. and Sheikholislami, Farzaneh}, biburl = {https://puma.ub.uni-stuttgart.de/bibtex/24e05806578a588c090b0cb29530dbd03/fabian}, doi = {10.1016/j.molimm.2009.01.021}, edition = {2009/03/03}, interhash = {f28998c7ff843e6641ac2fd36717ae73}, intrahash = {4e05806578a588c090b0cb29530dbd03}, isbn = {0161-5890}, issn = {01615890}, journal = {Molecular Immunology}, keywords = {2009 izi kontermann}, number = {8-9}, pages = {1814--1823}, pmid = {19249099}, timestamp = {2023-06-29T13:07:55.000+0200}, title = {{Cell selection and characterization of a novel human endothelial cell specific nanobody}}, url = {https://www.ncbi.nlm.nih.gov/pubmed/19249099}, volume = 46, year = 2009 }